array:23 [ "pii" => "S2173578623000756" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2023.06.011" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "1568" "copyright" => "AEU" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2023;47:471-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S021048062300089X" "issn" => "02104806" "doi" => "10.1016/j.acuro.2023.05.007" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "1568" "copyright" => "AEU" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "edi" "cita" => "Actas Urol Esp. 2023;47:471-3" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Experiencia inicial y propuesta de seguimiento del tumor de vejiga no músculo infiltrante de alto riesgo mediante el uso de Bladder Epicheck®" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "471" "paginaFinal" => "473" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 314 "Ancho" => 2091 "Tamanyo" => 82218 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Propuesta de seguimiento a 5 años mediante uso de Bladder Epicheck® en TVNMI-AR.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">BE: Bladder Epicheck®; m: meses; ECO: ecografía urinaria; UIV: urografía intravenosa; UROTC: tomografía computarizada con fase excretora.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Caño Velasco, L. Polanco Pujol, J.C. Moreno Cortés, A. Lafuente Puentedura, C. Hernández Fernández" "autores" => array:5 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Caño Velasco" ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Polanco Pujol" ] 2 => array:2 [ "nombre" => "J.C." "apellidos" => "Moreno Cortés" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Lafuente Puentedura" ] 4 => array:2 [ "nombre" => "C." "apellidos" => "Hernández Fernández" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173578623000756" "doi" => "10.1016/j.acuroe.2023.06.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578623000756?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S021048062300089X?idApp=UINPBA00004N" "url" => "/02104806/0000004700000008/v1_202310020523/S021048062300089X/v1_202310020523/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173578623000392" "issn" => "21735786" "doi" => "10.1016/j.acuroe.2023.03.003" "estado" => "S300" "fechaPublicacion" => "2023-10-01" "aid" => "1532" "copyright" => "AEU" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Actas Urol Esp. 2023;47:474-87" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Open versus robotic-assisted kidney transplantation: A systematic review by the European Association of Urology (EAU) – Young Academic Urologists (YAU) Kidney Transplant Working Group" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "474" "paginaFinal" => "487" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Trasplante renal abierto frente a trasplante renal asistido por robot: revisión sistemática del grupo de trabajo de trasplante renal de la sección de Jóvenes Urólogos Académicos (YAU) de la Asociación Europea de Urología (EAU)" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3066 "Ancho" => 2917 "Tamanyo" => 470807 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">PRISMA Flow Chart.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Territo, A.S. Bajeot, B. Mesnard, R. Campi, A. Pecoraro, V. Hevia, A. Piana, N. Doumerc, A. Breda, R. Boissier, T. Prudhomme" "autores" => array:11 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Territo" ] 1 => array:2 [ "nombre" => "A.S." "apellidos" => "Bajeot" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Mesnard" ] 3 => array:2 [ "nombre" => "R." "apellidos" => "Campi" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Pecoraro" ] 5 => array:2 [ "nombre" => "V." "apellidos" => "Hevia" ] 6 => array:2 [ "nombre" => "A." "apellidos" => "Piana" ] 7 => array:2 [ "nombre" => "N." "apellidos" => "Doumerc" ] 8 => array:2 [ "nombre" => "A." "apellidos" => "Breda" ] 9 => array:2 [ "nombre" => "R." "apellidos" => "Boissier" ] 10 => array:2 [ "nombre" => "T." "apellidos" => "Prudhomme" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0210480623000402" "doi" => "10.1016/j.acuro.2023.01.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0210480623000402?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578623000392?idApp=UINPBA00004N" "url" => "/21735786/0000004700000008/v3_202402041430/S2173578623000392/v3_202402041430/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience and follow-up proposal" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "471" "paginaFinal" => "473" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Caño Velasco, L. Polanco Pujol, J.C. Moreno Cortés, A. Lafuente Puentedura, C. Hernández Fernández" "autores" => array:5 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Caño Velasco" "email" => array:2 [ 0 => "jorcavel@gmail.com" 1 => "jorge.cano@salud.madrid.org" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Polanco Pujol" ] 2 => array:2 [ "nombre" => "J.C." "apellidos" => "Moreno Cortés" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Lafuente Puentedura" ] 4 => array:2 [ "nombre" => "C." "apellidos" => "Hernández Fernández" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Experiencia inicial y propuesta de seguimiento del tumor de vejiga no músculo infiltrante de alto riesgo mediante el uso de Bladder Epicheck®" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 314 "Ancho" => 2091 "Tamanyo" => 81029 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0235" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">5-year follow-up strategy using Bladder Epicheck® in HR-NMIBC. BE: Bladder Epicheck®; m: months; URO-CT: excretory phase computed tomography; IVU: intravenous urography; urinary US: urinary ultrasound.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Bladder cancer is the 7th most common cancer in men worldwide and the 10th if we consider both sexes, with an incidence rate (per 100,000 person/years) of 9.5 for men and 2.4 for women.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> The recurrence rate of non-muscle-invasive bladder cancer (NMIBC) ranges between 60%–70%, thus requiring a close follow-up, especially in high-risk cases (HR-NMIBC).<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">At the European level, the cost of bladder cancer was estimated at 4.9 billion euros in 2012, with healthcare expenditure accounting for nearly 60% of this value, which represents approximately 7000 euros per prevalent case and around 5% of the total healthcare costs for cancer.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> North American studies have estimated a total expenditure in the management of each NMIBC case of between 96,000 and 230,000 dollars.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The current clinical practice guidelines of the European Association of Urology (EAU)<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> recommend, although with a weak strength, that the surveillance of patients with HR-NMIBC includes urine cytology and cystoscopy every 3 months for the first 2 years after the initial TURB, every six months until the fifth year and yearly thereafter. Regular (yearly) upper tract imaging (computed tomography-intravenous urography [CT-IVU] or IVU) is also recommended.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Repeated cystoscopies during follow-up not only entail high healthcare costs but also have a negative impact on the quality of life (QoL) of patients due to the invasive nature of the test. Nearly 50% of patients who undergo cystoscopy experience pain during the procedure, with urinary urgency, hematuria, and the need for subsequent antibiotic therapy as undesirable side effects that occur with certain frequency.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">In recent years, we are witnessing the progressive development of different urinary biomarkers which are useful in the diagnosis and surveillance of bladder cancer<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> (Cx-Bladder,<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> ADX-Bladder™,<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> Xpert Bladder®,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> Bladder Epicheck®,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> Uromonitor®<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">12</span></a>). We must remember that the ideal biomarker, besides being cost-effective, should have a high sensitivity (Se) and specificity (Sp), as well as a fast and easy interpretation. On the other hand, considering that its main objective is to reduce the number of unnecessary cystoscopies, it should predominantly have a high negative predictive value (NPV).</p><p id="par0030" class="elsevierStylePara elsevierViewall">Today, their application in routine clinical practice is not consolidated. However, current EAU clinical guidelines<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,12</span></a> suggest that they might be used to replace and/or postpone cystoscopy as they may identify HG recurrences occurring in low/intermediate risk NMIBC. This is due to their high S and NPV in HG disease.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The studies performed in HR-NMIBC<a class="elsevierStyleCrossRefs" href="#bib0065"><span class="elsevierStyleSup">13–15</span></a> using Bladder Epicheck® show promising results despite their limited sample sizes. Bladder EpiCheck® (Nucleix Ltd., distributed by Palex Medical) is based on identification of DNA methylation changes associated with BC in a panel of 15 genomic biomarkers. Spontaneously voided urine samples undergo centrifugation for DNA extraction, which is digested using a methylation-sensitive restriction enzyme that cleaves DNA at recognition sequences if it is unmethylated, while leaving methylated sequences intact.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> Subsequently, it is amplified via real-time PCR and a numerical value called EpiScore™ is obtained. Episcore above 60 is considered positive for urothelial carcinoma.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Since its introduction as an ancillary test in our center, a tertiary public hospital in the Community of Madrid, we have carried out an analysis of its Sensitivity (Se), Specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV), by comparing it with cystoscopy, which is the gold standard in the follow-up of HR-NMIBC. For this purpose, a prospective analysis of 98 HR-NMIBC patients according to EAU 2020 criteria (T1 or HG/G3 tumors or carcinoma in situ (CIS) or low-grade Ta (LG) multiple, recurrent and larger than 3<span class="elsevierStyleHsp" style=""></span>cm tumors) followed in our center between June 2021 and February 2023 by white light cystoscopy, urine cytology and Bladder Epicheck® has been carried out.</p><p id="par0045" class="elsevierStylePara elsevierViewall">The median age of our series was 69 (IQR 65–75) years, with 80.6% being male. Of note, 87.7% received intravesical instillations after TURB (83.6% BCG and 4.1% mitomycin C). Of the series, 62.2% (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>61) were T1 (81.9%HG and 18.1%LG); 34.7% (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>34) Ta (85.3%HG and 14.7%LG); and only 3.1% (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3) presented CIS. There were 15 positive Bladder Epicheck® results.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Urothelial bladder cancer recurrence was confirmed in 8 patients (8.1%), of whom 6 underwent TURB of the bladder tumor (83.3%TaLG and 16.7%T1HG) and 2 are under active surveillance after the diagnosis of TaLG confirmed by biopsy with cold forceps. These two patients had negative cytology and a tumor size of less than 1<span class="elsevierStyleHsp" style=""></span>cm. There was no recurrence in the upper urinary tract.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Overall, we obtained Se values of 87.5%, Sp of 91.1%, PPV of 46.7%, and NPV of 98.8% for Bladder Epicheck® in the follow-up of HR-NMIBC in our series. However, the low sample size and the small number of recurrence events identified are the main limiting factors of our analysis.</p><p id="par0060" class="elsevierStylePara elsevierViewall">With the results obtained, supported by the high NPV and by relevant published literature, we have developed an alternative surveillance protocol that could be considered in the follow-up of HR-NMIBC (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">To ensure oncological safety, the first check-up – 3 months after diagnosis – requires a cystoscopy, preferably using PDD, NBI or IMAGE1 S™,<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> if available. Subsequently, the performance of cystoscopy and Bladder Epicheck® will be alternated. Using imaging tests when cystoscopy is not performed, could provide a higher Se, thus coinciding the annual URO-CT with the urinary biomarker check-up. The performance of urinary cytology in all stages of surveillance could be controversial. However, given its low cost, its adequate Se for HG, its non-invasive nature, and the dogma of its performance at the present time in the follow-up of HR-NMIBC, we believe that it can be maintained in the surveillance schedule as it does not deteriorate the patient’s QoL. This strategy would allow us to reduce the number of cystoscopies in HR-NMIBC to 50% with respect to the current EAU surveillance schedule, and this would probably have a positive impact on the economic and QoL spheres of our patients. However, we must not overlook the patient’s oncologic safety. Recently, an estimated delay in the detection of recurrence of 1.3 months has been established for patients with HR-NMIBC when applying a surveillance schedule similar to ours, in which cystoscopy and Bladder Epicheck®<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> are alternated in the same time frame. However, would a 40-day delay in diagnosis have clinical impact on our patients?</p><p id="par0070" class="elsevierStylePara elsevierViewall">Further prospective and multicenter studies, the improvement of current ones, and the development of new urinary biomarkers will provide us with information to optimize their use and application in the follow-up of NMIBC. In our opinion, the greatest impact, both in QoL and economic terms, will be produced when Bladder Epicheck® is applied to HR-NMIBC, as recently indicated by the group of Hekman et al.,<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a> which has reduced by up to 9% their social and healthcare expenditures in this group of patients.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0075" class="elsevierStylePara elsevierViewall">None.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 314 "Ancho" => 2091 "Tamanyo" => 81029 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0235" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">5-year follow-up strategy using Bladder Epicheck® in HR-NMIBC. BE: Bladder Epicheck®; m: months; URO-CT: excretory phase computed tomography; IVU: intravenous urography; urinary US: urinary ultrasound.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Cancer Today – IARC. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021 [Accessed April 2023]. Available from: <a target="_blank" href="https://gco.iarc.fr/today/online-analysis-table">https://gco.iarc.fr/today/online-analysis-table</a>." ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Gontero" 1 => "E. Compérat" 2 => "J.L. Dominguez Escrig" 3 => "F. Liedberg" 4 => "P. Mariappan" 5 => "A. Masson-Lecomte" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Libro" => array:1 [ "fecha" => "2023" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/introduction" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer—a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Nayak" 1 => "J. Cresswell" 2 => "P. Mariappan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.21037/tau-20-1333" "Revista" => array:6 [ "tituloSerie" => "Transl Androl Urol" "fecha" => "2021" "volumen" => "10" "paginaInicial" => "2737" "paginaFinal" => "2749" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34295759" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic burden of bladder cancer across the European Union" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Leal" 1 => "R. Luengo-Fernandez" 2 => "R. Sullivan" 3 => "J.A. Witjes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2015.10.024" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2016" "volumen" => "69" "paginaInicial" => "438" "paginaFinal" => "447" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26508308" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The burden of bladder cancer care: direct and indirect costs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Mossanen" 1 => "J.L. Gore" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MOU.0000000000000078" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Urol" "fecha" => "2014" "volumen" => "24" "paginaInicial" => "487" "paginaFinal" => "491" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24887047" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The community-based morbidity of flexible cystoscopy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "D.M. Burke" 1 => "D.C. Shackley" 2 => "P.H. O’Reilly" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1464-4096.2001.01899.x" "Revista" => array:6 [ "tituloSerie" => "BJU Int" "fecha" => "2002" "volumen" => "89" "paginaInicial" => "347" "paginaFinal" => "349" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11872022" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "F. Agreda Castañeda" 1 => "C.X. Raventós Busquets" 2 => "J. Morote Robles" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.acuro.2019.03.001" "Revista" => array:6 [ "tituloSerie" => "Actas Urol Esp (Engl Ed)" "fecha" => "2019" "volumen" => "43" "paginaInicial" => "404" "paginaFinal" => "413" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31097210" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B. Konety" 1 => "N. Shore" 2 => "A.K. Kader" 3 => "S. Porten" 4 => "S. Daneshmand" 5 => "T. Lough" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eururo.2019.04.035" "Revista" => array:6 [ "tituloSerie" => "Eur Urol" "fecha" => "2019" "volumen" => "76" "paginaInicial" => "238" "paginaFinal" => "243" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31103391" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reducing the frequency of follow-up cystoscopy in low-grade pTa non-muscle-invasive bladder cancer using the ADXBLADDER biomarker" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Rouprêt" 1 => "P. Gontero" 2 => "S.R.C. McCracken" 3 => "T. Dudderidge" 4 => "J. Stockley" 5 => "A. Kennedy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.euf.2022.02.006" "Revista" => array:6 [ "tituloSerie" => "Eur Urol Focus" "fecha" => "2022" "volumen" => "8" "paginaInicial" => "1643" "paginaFinal" => "1649" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35300937" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Cancel-Tassin" 1 => "M. Roupret" 2 => "U. Pinar" 3 => "C. Gaffory" 4 => "F. Vanie" 5 => "V. Ondet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00345-021-03629-1" "Revista" => array:6 [ "tituloSerie" => "World J Urol" "fecha" => "2021" "volumen" => "39" "paginaInicial" => "3329" "paginaFinal" => "3335" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33770241" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. D’Andrea" 1 => "F. Soria" 2 => "S. Zehetmayer" 3 => "K.M. Gust" 4 => "S. Korn" 5 => "J.A. Witjes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bju.14673" "Revista" => array:6 [ "tituloSerie" => "BJU Int" "fecha" => "2019" "volumen" => "123" "paginaInicial" => "959" "paginaFinal" => "967" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30653818" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Association of Urology – Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Laukhtina" 1 => "S.R. Shim" 2 => "K. Mori" 3 => "D. d’Andrea" 4 => "F. Soria" 5 => "P. Rajwa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.euo.2021.10.003" "Revista" => array:6 [ "tituloSerie" => "Eur Urol Oncol" "fecha" => "2021" "volumen" => "4" "paginaInicial" => "927" "paginaFinal" => "942" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34753702" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "DNA methylation analysis in urinary samples: a useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Pierconti" 1 => "E.D. Rossi" 2 => "T. Cenci" 3 => "A. Carlino" 4 => "V. Fiorentino" 5 => "A. Totaro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cncy.22657" "Revista" => array:6 [ "tituloSerie" => "Cancer Cytopathol" "fecha" => "2023" "volumen" => "131" "paginaInicial" => "158" "paginaFinal" => "164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36262084" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of Bladder Epicheck test in follow-up of patients with non-muscle invasive bladder cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Ragonese" 1 => "L.D. Gianfrancesco" 2 => "G. Palermo" 3 => "F. Pierconti" 4 => "M. Martini" 5 => "M. Foti" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.clgc.2022.03.009" "Revista" => array:6 [ "tituloSerie" => "Clin Genitourin Cancer" "fecha" => "2022" "volumen" => "20" "paginaInicial" => "e271" "paginaFinal" => "e275" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35871875" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.C.H. Hekman" 1 => "S.R.W. Wijn" 2 => "Y. Lotan" 3 => "T.M. Govers" 4 => "J.A. Witjes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00345-022-04252-4" "Revista" => array:6 [ "tituloSerie" => "World J Urol" "fecha" => "2023" "volumen" => "41" "paginaInicial" => "471" "paginaFinal" => "476" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36534153" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735786/0000004700000008/v3_202402041430/S2173578623000756/v3_202402041430/en/main.assets" "Apartado" => array:4 [ "identificador" => "6293" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735786/0000004700000008/v3_202402041430/S2173578623000756/v3_202402041430/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173578623000756?idApp=UINPBA00004N" ]
Journal Information
Vol. 47. Issue 8.
Pages 471-473 (October 2023)
Share
Download PDF
More article options
Vol. 47. Issue 8.
Pages 471-473 (October 2023)
Editorial
Bladder Epicheck® for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience and follow-up proposal
Experiencia inicial y propuesta de seguimiento del tumor de vejiga no músculo infiltrante de alto riesgo mediante el uso de Bladder Epicheck®
Visits
23
J. Caño Velasco
, L. Polanco Pujol, J.C. Moreno Cortés, A. Lafuente Puentedura, C. Hernández Fernández
Corresponding author
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
This item has received
Article information
These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail